A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal.
Affiliation
Department of Endocrinology, Christie Hospital, Manchester M20 4BX, United Kingdom.Issue Date
2002-04
Metadata
Show full item recordAbstract
Standard medical therapy for patients with acromegaly includes somatostatin analogs. Owing to the widespread expression of somatostatin receptors, these may be associated with unwanted effects, such as altered glucose tolerance and impaired gut hormone release. Pegvisomant is a novel pegylated GH analog that competes with wild-type GH for GH-receptor binding sites but contains a position 120, amino acid substitution that prevents functional GH receptor dimerization, a known prerequisite for GH signal transduction and generation of IGF-I. We have studied the short-term effects of these two therapies (pegvisomant 20 mg/d for 7 d and octreotide 50 microg thrice daily for 7 d) on glucose tolerance and stimulated gut hormone release in six healthy male volunteers in an open-label, random-order, cross-over study. Subjects were assessed at baseline (oral glucose tolerance test and standard mixed meal) and on d 6 and 7 of each therapy with a minimum washout of 2 wk between treatments. Area under the curve and peak responses were analyzed using one-way repeated-measures ANOVA (on ranks where appropriate). Pegvisomant had no effect on glucose tolerance or stimulated gut hormone response during an oral glucose tolerance test and a standard meal. In contrast, octreotide significantly increased fasting plasma glucose, lowered fasting plasma insulin, and led to deterioration in glucose tolerance; three subjects developed impaired glucose tolerance and one diabetes mellitus by World Health Organization criteria. Octreotide significantly impaired stimulated release of cholecystokinin, gastrin, insulin, and pancreatic polypeptide. In conclusion, pegvisomant, unlike octreotide, is not associated with deterioration in glucose tolerance and impairment of stimulated gut hormone release in normal males.Citation
A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. 2002, 87 (4):1797-804 J. Clin. Endocrinol. Metab.Journal
The Journal of Clinical Endocrinology and MetabolismDOI
10.1210/jc.87.4.1797PubMed ID
11932320Type
ArticleLanguage
enISSN
0021-972Xae974a485f413a2113503eed53cd6c53
10.1210/jc.87.4.1797
Scopus Count
Collections
Related articles
- Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
- Authors: Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov H
- Issue date: 2005 Oct
- Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
- Authors: Jawiarczyk A, Kałuzny M, Bolanowski M, Bednarek-Tupikowska G
- Issue date: 2008 Aug
- Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.
- Authors: Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP, Trainer PJ
- Issue date: 2003 Dec
- Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
- Authors: Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G
- Issue date: 2006 Mar
- Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
- Authors: Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA, Sharma A
- Issue date: 2007 Feb 1